CPC Scientific Inc

Founded in 2001, the CPC Scientific Group is a globally recognized Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in peptides and oligonucleotides. With nearly 25 years of experience, CPC Scientific has grown into one of the world’s leading tide-focused R&D organizations.

Through its fully integrated service model, CPC Scientific supports partners across every stage of drug development, from early discovery to late-phase development, large-scale manufacturing, and commercial production. Backed by deep expertise and robust infrastructure, CPC Scientific accelerates peptide and oligonucleotide programs from concept to commercialization.

Vision & Mission

CPC Scientific’s strategic aim is to accelerate and support peptide and oligonucleotide therapeutics development by delivering end-to-end quality services as a globally trusted CRDMO. Its inferred mission is to accelerate the discovery and development of peptide and oligonucleotide-based therapeutics and diagnostics by offering comprehensive, high-quality research-grade and GMP manufacturing services that extend from early discovery through to final commercialization. This ensures that life-changing therapies reach those who need them most by helping innovative medicines achieve regulatory approval more quickly, making breakthrough treatments accessible to patients, and thereby expanding access to high-quality, affordable drugs worldwide.

This is founded on an overall vision of offering world-class peptide and conjugate CRDMO services that support the pharmaceutical and biotech sectors with the vertical integration of drug development and manufacturing required to master the increasing complexity of new peptide- and oligonucleotide-based drugs.

Activities & Services

CPC Scientific combines the functions of a CRO for drug discovery with those of a CDMO for chemistry, manufacturing, and controls (CMC), and a CMO for commercial manufacturing. In addition, it offers peptide–oligonucleotide conjugate (POC), peptide–drug conjugate (PDC), and radionuclide–drug conjugate (RDC) platforms for leading-edge synthesis and scale-up.

The company’s services are grouped into five main activity streams:

• GMP Peptide Manufacturing– CPC Scientific specializes in large-scale, late-phase, and commercial peptide manufacturing, , with an annual peptide API production capacity of 1,000 kg and a per-batch peptide production capacity of 20–25 kg. It focuses on manufacturing synthetic peptides and oligonucleotides across early-phase development, late-phase development, and full commercial production, providing complete life-cycle support. Its manufacturing is supported by ample capacity, robust supply chains, and a more than 20-year proven track record in NCE and generic development, bulk-scale manufacturing, and regulatory compliance.
• Research Peptides: CPC Scientific is one of the world’s leading producers of highly customized peptides for direct supply to researchers. Alongside its thousands of ready-to-ship catalog peptides, it can perform virtually any peptide modification to produce custom-synthesized peptides from 2 to >200 amino acids in length, at purities up to 99%, to specific order.
• GMP Oligonucleotide Manufacturing: CPC Scientific’s manufacturing services for research-grade and clinical-grade oligonucleotides extend from initial discovery through clinical phases to full commercialization with regulatory filing. Based on typical 20–25-mer oligos, the entire manufacturing journey to bulk production—including process development, analytical method development and validation, stability studies, scale-up, and dossier development—can be completed in as little as eight months.
• Custom Oligonucleotide Manufacturing: CPC Scientific uses its leading-edge solid-phase manufacturing protocols to offer contract manufacturing of highly specialized oligonucleotides, including ASO, siRNA, miRNA, PMO (morpholinos), aptamers, CpG, and decoy oligonucleotides, as well as most types of modifications, including peptide–oligonucleotide conjugates (POCs, PPMOs). These services include scale-up development and comprehensive analytical services such as testing for structural integrity, endotoxin content, and ICH Q1–Q3 quality standards.
• Peptide–Oligonucleotide Conjugate Services: CPC Scientific has dedicated facilities for the chemical modification of ASO, siRNA, CpG, miRNA, and aptamer oligonucleotides, and the production of peptide–oligonucleotide conjugates (POCs). These have become the basis for many breakthrough therapies for indications such as neurodegenerative diseases, ophthalmic disorders, cancer, respiratory diseases, and viral infections, due to their vastly superior cellular uptake, cell-specific delivery, tissue targeting, and intracellular distribution. Its parallel synthetic approach provides a wide range of conjugation methods and attachment sites for assembling peptide–oligonucleotide conjugates, including amide bonds, disulfide bonds, thioether linkages, and triazole “click chemistry.”

Company History & Structure

Now headquartered in Rocklin, near Sacramento, California, CPC Scientific is a private company and a subsidiary of Medtide Inc. With Dr. Lee as CEO, the CPC Scientific leadership team also includes Theresa Tao Cheng as President, Irvine Skeoch as Chief Operating Officer, and Baosheng Liu as Chief Solution Officer.

CPC Scientific’s parent company, Medtide Inc., is the third-largest peptide-focused CRDMO worldwide by sales revenue, holding a 1.5% global market share in 2023, according to Frost & Sullivan. CPC Scientific are also recognized as one of the most comprehensive providers globally in terms of complete life cycle support.

The CPC Scientific group was founded in 2001 by Dr. Shawn Lee.

In 2004,  CPC Scientific’s first peptide facility integrated synthesis, purification, and quality control under one roof was established in Hangzhou. In 2005, ISO 9001 certification for international standardization of quality management systems (QMS) was achieved and the US company was established. In 2006, the company opened its GMP peptide production plant in Hangzhou, China and GMP inspection by the National Medical Products Administration (NMPA). Since 2011, one of the first peptide CDMOs in Asia to pass a US FDA inspection. Currently, CPC Scientific also has business office in Milpitas, near San Jose in California’s Silicon Valley.

In June 2025, parent company Medtide Inc. was officially listed on the main board of the Hong Kong Stock Exchange, marking a major milestone in the group’s continued growth and global impact.

Quality, Regulatory, and Standards

CPC Scientific’s impressive regulatory credentials include numerous FDA cGMP inspections passed, ISO 9001 and ISO 13485 quality certifications, and hundreds of global filings supported by the US FDA, EMA in the EU, China’s NMPA, Australia’s TGA, and South Korea’s MFDS.

It operates under FDA cGMP, ICH, and WHO guidelines and can provide comprehensive IND/NDA regulatory support globally.

The company can also claim to operate the world’s largest research peptide facility successfully audited by the FDA and major pharmaceutical organizations.